VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company's pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering. VERAXA plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.
The company's executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
This update underscores the company's focus on its proprietary BiTAC platform, which it believes offers a differentiated approach to T-cell engagers. The company's strategy of monetizing non-core assets to fund its lead programs could be a key factor in its ability to reach key milestones without diluting existing shareholders. The interest from pharmaceutical partners suggests that the BiTAC platform may address unmet needs in solid tumor treatment.
For more details, the full press release is available at https://ibn.fm/xTF5q.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats.
Investors can find the latest news and updates relating to VRXA in the company's newsroom at http://ibn.fm/VRXA.
